Recent approaches to novel antibacterials designed after LPS structure and biochemistry

Luca Gabrielli, Alice Capitoli, Davide Bini, Francesca Taraballi, Cristina Lupo, Laura Russo, Laura Cipolla

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Lipopolysaccharides (LPSs), which constitute the lipid portion of the outer leaflet of Gram-negative bacteria, are essential for growth, and are responsible for a variety of biological effects associated with Gram-negative sepsis. LPSs are amphiphilic molecules comprising three regions: lipid A, the core region, and a polysaccharide portion; the lipid A was proven to represent the toxic principle of endotoxic active lipopolysaccharides. In addition, it is known that the minimal conserved structure of LPS is the lipophylic oligoasaccharidic structure containing Kdo residues linked to the-LipA moiety. Thus, the design and development of novel antibacterial drugs can focus on different aspects, related to the biosynthesis and chemical features of LPS: 1) Inhibitors of lipid A biosynthesis 2) Inhibitors of Kdo biosynthesis. Both Kdo and Lipid A are needed for the construction of the minimum structural element Kdo2-LipidA, needed for bacterial survival. Any inhibitors acting on the biogenetic pathway of this molecule can act as antibacterial. 3) Antagonists of the interaction between endotoxins and the host receptors: LPS is recognised by the CD14 and the Toll-like receptor (TLR)- 4/MD2 complex, where Lipid A is the crucial moiety in the interaction. Any drug acting as an antagonist of this process can have antisepsis potential. Considerable efforts have been made in this direction to identify natural or synthetic molecules able to interfere with the interaction between LPS and inflammatory cells. This review will highlight recent efforts in the design and biological activity of enzyme inhibitors and antagonist acting on the 3 key aspects outlined above.

Original languageEnglish
Pages (from-to)1458-1471
Number of pages14
JournalCurrent Drug Targets
Volume13
Issue number11
DOIs
Publication statusPublished - 2012

Fingerprint

Biochemistry
Lipid A
Lipopolysaccharides
Biosynthesis
Molecules
CD14 Antigens
Antisepsis
Toll-Like Receptor 4
Poisons
Enzyme Inhibitors
Bioactivity
Endotoxins
Pharmaceutical Preparations
Polysaccharides
Gram-Negative Bacteria
Bacteria
Sepsis
Lipids
Growth

Keywords

  • Antibacterials
  • Gram-negative bacteria
  • Kdo
  • LPS
  • Septic shock
  • Toll-like receptor 4

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Recent approaches to novel antibacterials designed after LPS structure and biochemistry. / Gabrielli, Luca; Capitoli, Alice; Bini, Davide; Taraballi, Francesca; Lupo, Cristina; Russo, Laura; Cipolla, Laura.

In: Current Drug Targets, Vol. 13, No. 11, 2012, p. 1458-1471.

Research output: Contribution to journalArticle

Gabrielli, L, Capitoli, A, Bini, D, Taraballi, F, Lupo, C, Russo, L & Cipolla, L 2012, 'Recent approaches to novel antibacterials designed after LPS structure and biochemistry', Current Drug Targets, vol. 13, no. 11, pp. 1458-1471. https://doi.org/10.2174/138945012803530242
Gabrielli, Luca ; Capitoli, Alice ; Bini, Davide ; Taraballi, Francesca ; Lupo, Cristina ; Russo, Laura ; Cipolla, Laura. / Recent approaches to novel antibacterials designed after LPS structure and biochemistry. In: Current Drug Targets. 2012 ; Vol. 13, No. 11. pp. 1458-1471.
@article{85d1fc9475084e62a2278ed5fe26d7a9,
title = "Recent approaches to novel antibacterials designed after LPS structure and biochemistry",
abstract = "Lipopolysaccharides (LPSs), which constitute the lipid portion of the outer leaflet of Gram-negative bacteria, are essential for growth, and are responsible for a variety of biological effects associated with Gram-negative sepsis. LPSs are amphiphilic molecules comprising three regions: lipid A, the core region, and a polysaccharide portion; the lipid A was proven to represent the toxic principle of endotoxic active lipopolysaccharides. In addition, it is known that the minimal conserved structure of LPS is the lipophylic oligoasaccharidic structure containing Kdo residues linked to the-LipA moiety. Thus, the design and development of novel antibacterial drugs can focus on different aspects, related to the biosynthesis and chemical features of LPS: 1) Inhibitors of lipid A biosynthesis 2) Inhibitors of Kdo biosynthesis. Both Kdo and Lipid A are needed for the construction of the minimum structural element Kdo2-LipidA, needed for bacterial survival. Any inhibitors acting on the biogenetic pathway of this molecule can act as antibacterial. 3) Antagonists of the interaction between endotoxins and the host receptors: LPS is recognised by the CD14 and the Toll-like receptor (TLR)- 4/MD2 complex, where Lipid A is the crucial moiety in the interaction. Any drug acting as an antagonist of this process can have antisepsis potential. Considerable efforts have been made in this direction to identify natural or synthetic molecules able to interfere with the interaction between LPS and inflammatory cells. This review will highlight recent efforts in the design and biological activity of enzyme inhibitors and antagonist acting on the 3 key aspects outlined above.",
keywords = "Antibacterials, Gram-negative bacteria, Kdo, LPS, Septic shock, Toll-like receptor 4",
author = "Luca Gabrielli and Alice Capitoli and Davide Bini and Francesca Taraballi and Cristina Lupo and Laura Russo and Laura Cipolla",
year = "2012",
doi = "10.2174/138945012803530242",
language = "English",
volume = "13",
pages = "1458--1471",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

TY - JOUR

T1 - Recent approaches to novel antibacterials designed after LPS structure and biochemistry

AU - Gabrielli, Luca

AU - Capitoli, Alice

AU - Bini, Davide

AU - Taraballi, Francesca

AU - Lupo, Cristina

AU - Russo, Laura

AU - Cipolla, Laura

PY - 2012

Y1 - 2012

N2 - Lipopolysaccharides (LPSs), which constitute the lipid portion of the outer leaflet of Gram-negative bacteria, are essential for growth, and are responsible for a variety of biological effects associated with Gram-negative sepsis. LPSs are amphiphilic molecules comprising three regions: lipid A, the core region, and a polysaccharide portion; the lipid A was proven to represent the toxic principle of endotoxic active lipopolysaccharides. In addition, it is known that the minimal conserved structure of LPS is the lipophylic oligoasaccharidic structure containing Kdo residues linked to the-LipA moiety. Thus, the design and development of novel antibacterial drugs can focus on different aspects, related to the biosynthesis and chemical features of LPS: 1) Inhibitors of lipid A biosynthesis 2) Inhibitors of Kdo biosynthesis. Both Kdo and Lipid A are needed for the construction of the minimum structural element Kdo2-LipidA, needed for bacterial survival. Any inhibitors acting on the biogenetic pathway of this molecule can act as antibacterial. 3) Antagonists of the interaction between endotoxins and the host receptors: LPS is recognised by the CD14 and the Toll-like receptor (TLR)- 4/MD2 complex, where Lipid A is the crucial moiety in the interaction. Any drug acting as an antagonist of this process can have antisepsis potential. Considerable efforts have been made in this direction to identify natural or synthetic molecules able to interfere with the interaction between LPS and inflammatory cells. This review will highlight recent efforts in the design and biological activity of enzyme inhibitors and antagonist acting on the 3 key aspects outlined above.

AB - Lipopolysaccharides (LPSs), which constitute the lipid portion of the outer leaflet of Gram-negative bacteria, are essential for growth, and are responsible for a variety of biological effects associated with Gram-negative sepsis. LPSs are amphiphilic molecules comprising three regions: lipid A, the core region, and a polysaccharide portion; the lipid A was proven to represent the toxic principle of endotoxic active lipopolysaccharides. In addition, it is known that the minimal conserved structure of LPS is the lipophylic oligoasaccharidic structure containing Kdo residues linked to the-LipA moiety. Thus, the design and development of novel antibacterial drugs can focus on different aspects, related to the biosynthesis and chemical features of LPS: 1) Inhibitors of lipid A biosynthesis 2) Inhibitors of Kdo biosynthesis. Both Kdo and Lipid A are needed for the construction of the minimum structural element Kdo2-LipidA, needed for bacterial survival. Any inhibitors acting on the biogenetic pathway of this molecule can act as antibacterial. 3) Antagonists of the interaction between endotoxins and the host receptors: LPS is recognised by the CD14 and the Toll-like receptor (TLR)- 4/MD2 complex, where Lipid A is the crucial moiety in the interaction. Any drug acting as an antagonist of this process can have antisepsis potential. Considerable efforts have been made in this direction to identify natural or synthetic molecules able to interfere with the interaction between LPS and inflammatory cells. This review will highlight recent efforts in the design and biological activity of enzyme inhibitors and antagonist acting on the 3 key aspects outlined above.

KW - Antibacterials

KW - Gram-negative bacteria

KW - Kdo

KW - LPS

KW - Septic shock

KW - Toll-like receptor 4

UR - http://www.scopus.com/inward/record.url?scp=84866916500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866916500&partnerID=8YFLogxK

U2 - 10.2174/138945012803530242

DO - 10.2174/138945012803530242

M3 - Article

C2 - 22876888

AN - SCOPUS:84866916500

VL - 13

SP - 1458

EP - 1471

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 11

ER -